San Diego, California — According to state and local economic development sources Acadia Pharmaceuticals plans to invest $2,464,072.00 to build out 28,652 square feet of new space in San Diego. The company plans to occupy the new space at 12830 El Camino Real in San Diego, on or about April 1, 2021. According to the company website Acadia aspires to enable brighter moments for patients and their loved ones. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.

To learn more about Acadia Pharmaceuticals, visit http://www.acadia-pharm.com/

Company Contact:
Stephen Davis, Chief Executive Officer
https://www.linkedin.com/in/steve-davis-74b86910/
858-558-2871

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved